Professor John Greenman
Professor of Tumour Immunology
|Biography||John is a tumour immunologist with extensive experience of developing lab on a chip technology for analysing tumour biopsies.
He has published over 150 peer-reviewed publications and his immunobiology group works closely with clinicians, chemists and engineers.
The majority of his research work has focused on tumours of the head and neck region, identifying novel markers of progression or treatment response.
1991-1995 Post-doctoral Research Fellow, Sir William Dunn School of Pathology, MRC Cellular Immunology Unit, University of Oxford
1995-1999 Lecturer in Immunology, Dept of Surgery, University of Hull
1999-2004 Senior Lecturer in Tumour Immunology, University of Hull
2004- 2009 Reader in Tumour Immunology, University of Hull
Currently a member of the NC3Rs David Sainsbury Fellowship Panel 2015 -
REF2014 - Appointed as Output Assessor for Panel UoA3 (2014)
|Research Interests||Coming from an immunology background, Professor Greenman is extremely interested in understanding how the immune system is often subverted during carcinogenesis, and more importantly how such knowledge can be used clinically (diagnostically, prognostically or therapeutically).
Current and recent grants
H2020-MSCA-RISE-2016, €976,000 (€153k to Hull) (Greenman). Blood test for clinical therapy guidance of non-small cell lung cancer patients.
Yorkshire Cancer Research, €99,198 (Lind and Greenman). Peripheral blood detection of EGFR status in lung cancer patients. 01/11/2016 - 31/10/2018
Innovate UK/EPSRC €496,000 (€193k to Hull) (Greenman, Green, Cawthorne). Development of a multi-purpose small animal phantom for pre-clinical radiotherapy studies. 01/03/2016 - 28/02/2018.
Yorkshire Cancer Research €123,312 (Archibald, Madden & Greenman). Chemokine receptor targeted therapies. 01/02/2014 - 31/01/2016.
British Lung Foundation €24,800 (Loveday, Lind, Haswell & Greenman). Development of microfluidic device for response to chemotherapy in malignant mesothelioma. 01/10/2013 - 30/09/2015.
Technology Strategy Board Sepsis I: Multi-pathogen detection and/or simple discrimination €399,000 (Greenman, Dyer, Haswell, BioGene Ltd). Rapid, on-chip, multiplexed detection of sepsis-causing organisms from blood samples. 01/09/2012 - 31/08/2015.
FP7-SME-2012. Point-of-care blood device for fast and reliable prediction of drug response in non-small cell lung carcinoma patients from blood samples (LungCARD 315586) University of Hull (Haswell & Greenman); Hull and East Riding NHS Trust (Lind & Greenman) (€306,000 to Hull; 1.2M Euro total) 01/01/2013 - 28/2/2014.
NC3R €450,000 (Greenman, Madden, Flynn, Haswell, Maraveyas). Replacement of animal models for tumour biology with a multifunctional microfluidic-based approach. 01/10/2011 - 30/09/2014.
NIHR (i4i programme). €667,542 (Elliott, Wadhawan, Singh, MacFie, Greenman). Development of a placement sensing nasogastric tube. 01/07/2011 - 30/06/2014.
Hull and East Riding Cardiac Trust. €76,128 (Greenman, Jones, Dyer, Wadhawan, Haswell, Griffin, Seymour) Integrated microfluidic devices for real-time measurement of biochemical changes in heart tissue. 01/03/2011 - 30/11/2012.
Heart Research UK €199,728 (Greenman, Haswell and Seymour). Development of microfluidic devices for analysis of function in normal and diseased cardiac tissue. 10/2007 - 09/2011.
EPSRC EP/H007385 €210,949 (Haswell & Greenman). Commercialisation of lab-on-a-chip technology for DNA profiling. 08/2009 - 07/2010.
|Teaching and Learning||BSc programmes
- Clinical Microbiology and Immunology
- Professional and Research skills for Biomedical Sciences
- Reviews in Biomedical Science
- Final Year Research Projects, 20 and 40 credit
- Tumour Immunology and Microenvironment
- Organ-specific Cancers: From Bench to Bedside
- Research Project and Dissertation